MI Trials offer patients and physicians access to the latest drugs being developed to improve clinical outcomes. However, awareness of available trials is low and overall participation in oncology trials is less than five percent. Caris helps increase awareness and participation of clinical trials through Caris Trial Solutions.
Comprehensive molecular profiling of DNA, RNA and proteins to identify patients for appropriate biomarker-driven trials.
Alerts clinician of patient-trial match and provides consultations on trial opportunities for identified patients.
Provides physician with expertise on Caris molecular profiling results.
MI Trials offer patients and physicians access to the latest drugs in development. However, clinical trial awareness is low and trial site activation can take months. Caris Right-In-Time Clinical Trial Solutions improves the way physicians and patients connect with clinical trials by combining best-in-class tumor profiling with Right-In-Time (RIT) clinical trial capabilities to deliver on-demand patient-centric clinical trial solutions.
Enhancing access to the latest and most promising treatments and clinical trials quickly – in days, not months.
Assessing DNA, RNA and Proteins reveals a molecular blueprint to guide more precise treatment decisions, including clinical trial options.
More than 1,120 new drugs are in development and over 6,000 clinical trials are available for cancer patients.